Mark Spring

Mark Spring website

Mark brings 25 years of experience in life sciences to his role, including financial leadership of private and public, domestic and multinational companies. He most recently served as Co-founder and CFO of Secura Bio, a commercial-stage oncology therapeutics company. He previously held the role of CFO for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless and Genoptix. Mark has extensive M&A experience with significant roles in transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus and Genoptix. He additionally served in senior-level financial positions at Baxter Healthcare and Pricewaterhouse Coopers.

Mark holds a BA in Business Administration from Monmouth College. He also completed post-graduate studies at the University of Texas, Dallas and is a Certified Public Accountant.

Select Achievements

  • Led finance, IT, human resources and facilities functions for newly formed pharma company that acquired two oncology products within 18 months and conducted commercial operations in 15+ countries
  • Led finance, facilities and risk management for $100 million oncology diagnostic business acquired from Novartis, which was restructured to profitability and successfully divested within 20 months


Strategic and operational leadership
Equity and debt financings
M&A, licensing and collaborations
Financial reporting, planning and analysis
Financial controls